Last reviewed · How we verify
NCT05153200
Early Changes in Pain, Disease Activity, and Ultrasound Evidence of Inflammatory Synovitis in Patients Receiving JAK-inhibitor vs. TNF-inhibitor Therapy for Active Rheumatoid Arthritis: A Feasibility Study.
Phase 4 trial testing Upadacitinib in Rheumatoid Arthritis in 40 participants. Status unknown.
1 June 2023
Quick facts
| Lead sponsor | Ottawa Hospital Research Institute |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 1 January 2022 |
| Primary completion | 1 June 2023 |
| Estimated completion | 1 June 2023 |
Drugs / interventions tested
- Upadacitinib — full drug profile →
- Adalimumab (ADALIMUMAB) — full drug profile →
Conditions studied
- Rheumatoid Arthritis — all drugs for Rheumatoid Arthritis →
Sponsor
Ottawa Hospital Research Institute
Who can join
18 and older, any sex, with Rheumatoid Arthritis. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Recruitment Rate
Time frame: 1 year
Number of participants recruited to study -
Retention Rate
Time frame: 6 months
Proportion of participants who complete the 6 months of follow-up
Sponsor's own description
The purpose of this phase 4 pilot study is to assess 1-year recruitment, and 6-month retention rates for participants with rheumatoid arthritis (RA) recruited to this study. Secondarily, we aim to study the difference in multifaceted pain scoring and Musculoskeletal Ultrasound (MSK-US)-detected synovitis between those treated with Upadacitinib vs Adalimumab.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeting rheumatoid arthritis: a molecular perspective on biologic therapies and clinical progress.
Jain A, Bishnoi M, Prajapati SK, Acharya S, et al · · 2025 · cited 3× · PMID 40707975 · DOI 10.1186/s13036-025-00534-8 -
Large-scale multi-trait genome-wide analysis for inflammatory bowel disease reveals new insights into its molecular mechanisms and emphasizes the roles of systemic immune regulation.
Zhu Z, Shi L, Li H, Wang X, et al · · 2025 · PMID 41308126 · DOI 10.1093/bib/bbaf633
Verify or expand the search:
- PubMed search for NCT05153200
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Upadacitinib
Trials testing the same drug.
- NCT07502339 — Upadacitinib in Patients Hospitalized With Acute Severe Ulcerative Colitis · Phase 4 · not yet recruiting
- NCT07492251 — Upadacitinib in Adult Patients With Erosive Mucosal Lichen Planus and Lichen Planopilaris: a Prospective Multicenter Ran · Phase 2 · not yet recruiting
- NCT06016517 — Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis · not yet recruiting
- NCT07546097 — Comparative Effectiveness of Upadacitinib vs Corticosteroids as First-Line Therapy for Acute Severe Ulcerative Colitis（U · Phase 4 · recruiting
- NCT07510191 — TNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With Suboptimal Response · Phase 4 · recruiting
Other recruiting trials for Rheumatoid Arthritis
Currently open trials in the same condition.
- NCT07433335 — A Study to Assess the Safety and Tolerability of SR-878 in Patients With Rheumatoid Arthritis · Phase 1 · recruiting
- NCT07491016 — Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis · recruiting
- NCT07171983 — A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis · Phase 1 · recruiting
- NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
- NCT07363590 — A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) · Phase 1 · recruiting
Other Ottawa Hospital Research Institute trials
Trials by the same sponsor.
- NCT07464080 — Advanced Brain Imaging-TKA (fMRI-TKA) · NA · recruiting
- NCT07171567 — Vacuum Therapy for the Treatment of Penile Numbness/Sensory Changes · EARLY_PHASE1 · recruiting
- NCT07177833 — Title Fractioned CO2 Laser in the Treatment of Chronic Phase Peyronie's Disease · Phase 1 · recruiting
- NCT07058025 — Mesenchymal Stromal Cell Therapy to Prevent Bronchopulmonary Dysplasia in Extreme Preterm Infants · Phase 2 · not yet recruiting
- NCT06929767 — Do Blood Tests Help to Decide Which Patients With Flares of Chronic Obstructive Pulmonary Disease (COPD) Need Antibiotic · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05153200 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 1 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ottawa Hospital Research Institute
- Last refreshed: 29 November 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05153200.